个人简介

叶文才，教授，博士生导师，暨南大学双一流药学学科负责人、生物活性分子与成药性优化全国重点实验室主任，曾获国家杰青、国家高层次人才计划特聘教授，入选俄罗斯工程院外籍院士、英国皇家化学会会士、新世纪百千万人才工程国家级人选、广东南粤百杰，并获全国模范教师、全国优秀科技工作者称号。1983年7月毕业于南京药学院(现中国药科大学)中药学专业，获学士学位；1983年8月−1988年10月在安徽中医药高等专科学校任教；1988年11月−1997年7月在中国药科大学天然药物化学教研室任教，先后任讲师、副教授；1997年8月−2001年10月在香港科技大学化学系学习，获博士学位；2001年12月起任中国药科大学教授、博士生导师；2002年8月−2015年11月先后担任暨南大学中药及天然药物研究所常务副所长、中药系主任、药学院副院长、院长。2014年10月−2023年10月任暨南大学副校长。现兼任国家药典委员会委员、中国药学会理事、中药和天然药物专业委员会副主任委员及广东省药学会副理事长、世界中医药学会联合会中药化学专业委员会副会长、第八届教育部科学技术委员会(药学与中医药学部)委员、广东省人民政府参事，及《Engineering》杂志医药卫生学科执行主编、《现代中药研究与实践》杂志主编和《Chem Biodivers》等10余种国内外专业学术期刊编委。

一直从事中药和天然药物活性成分、作用机制和靶标、创新药物研发等研究，在新颖结构天然生物活性分子定向发现及高效仿生合成、天然药物化学生物学、创新药物研发等方面取得了系列创新研究成果。已发表研究论文920余篇，其中在Chem、Nat Metab、Gut、JACS、J Clin Invest、Angew Chem Int Ed、Hepatology、STTT、Mol Psychiatry、Chem Sci、Org Lett、J Nat Prod等SCI收录杂志发表论文550余篇，总他引15000余次，连续被列入Elsevier中国高被引学者榜单；获授权国内外发明专利90余项，被转化30余项；研发多个候选新药，其中主持(药学部分)研发的治疗消化不良天然药物枳实总黄酮片获批上市、地乌风湿安胶囊已完成三期临床试验；主持国家重点研发计划、国家自然科学基金重点项目、国家自然科学基金-广东联合基金重点项目、国家新药创制重大专项、国家高层次人才计划创新团队、广东省珠江人才计划首批本土创新科研团队、广东省重点领域研发计划、广东省和广州市重大科技专项等科研项目40余项。获第二届全国创新争先奖，以第一完成人获国家科技进步奖二等奖1项、广东省科学技术奖一等奖3项，并获国家教学成果奖二等奖1项、中国产学研合作创新成果奖一等奖2项、中国专利优秀奖1项，及中国药学发展奖、广东省丁颖科技奖、国务院政府特殊津贴，成果入选“2017中国十大医学进展”。讲授了多门本科生和研究生课程，培养硕士和博士研究生170余名。

研究方向

1.中药及天然药物活性成分研究

2.活性天然产物的化学生物学研究

3.中药及天然药物来源的创新药物研究

代表性论文

1.Song JG, Zheng J, Wei RJ, Huang YL, Jiang J, Ning GH, Wang Y*, Lu W*, Ye WC*, Li D*. Crystalline mate for structure elucidation of organic molecules. Chem, 2024, 10(3): 924-937. (IF: 23.5)

2.Wang CR, Huang MH, Lin YN, Zhang YN, Pan JH, Jiang C, Cheng MJ, Li SR, He WZ, Li ZQ, Tu ZC, Fan J, Zeng HH, Lin JH, Wang YJ, Yao N, Liu TZ, Qi Q, Liu XN, Zhang ZM, Chen MF*, Xia LP*, Zhang DM*, Ye WC*. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nature Metabolism, 2023, 5(10): 1765-1786. (IF: 20.8)

3.Li XB, Pan JH, Liu TZ, Yin WQ, Miao Q, Zhao Z, Gao YF, Zheng W, Li H, Deng R, Huang DD, Qiu SH, Zhang YR, Qi Q, Deng LJ, Huang MH, Tang P MK, Cao YH, Chen MF*, Ye WC*, Zhang DM*. Novel TCF21high pericyte subpopulation promotes colorectal cancer metastasis by remodelling perivascular matrix. Gut, 2023, 72(4): 710-721. (IF: 24.5) 

4.Wen Q, Huang MH, Xie JW, Liu RY, Miao Q, Huang JJ, Zhang JQ, lyu WY, Qi M, Wu CY, Qi Q, Zhang ZJ, Deng R, Wang CR, Chen ZS, Zhang DM*, Ye WC*, Chen MF*. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resistance Updates, 2023, 69: 100975. (IF: 24.3)

5.Huang MH, Lin YN, Wang CR, Deng LJ, Chen MF, Assaraf YG, Chen ZS*, Ye WC*, Zhang DM*. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resistance Updates, 2022, 64: 100849. (IF: 24.3) 

6.Wang J, Song JG, Zhong DL, Duan ZZ, Peng ZJ, Tang W, Song QY, Huang XJ, Hu LJ*, Wang Y*, Ye WC*. Biomimetic synthesis of an antiviral cinnamoylphloroglucinol collection from Cleistocalyx operculatus: a synthetic strategy based on biogenetic building blocks. Angewandte Chemie-International Edition, 2023, 62(50), e202312568. (IF: 16.6)

7.He QF, Wu ZL, Li L, Sun WY, Wang GY, Jiang RW, Hu LJ, Shi L, He RR, Wang Y*, Ye WC*. Discovery of neuritogenic Securinega alkaloids from Flueggea suffruticosa by a building-block-based molecular network strategy. Angewandte Chemie-International Edition, 2021, 60: 19609. (IF: 16.6) 

8.Wu ZL, Zhao BX, Huang XJ, Tang GY, Shi L, Jiang RW, Liu X, Wang Y*, Ye WC*. Suffrutines A and B: a pair of Z/E isomeric indolizidine alkaloids from the roots of Flueggea suffruticosa. Angewandte Chemie, International Edition, 2014, 53: 5796−5799. (IF: 16.6)

9.Qi M, Fan S, Huang M, Pan J, Li Y, Miao Q, Lyu W, Li X, Deng L, Qiu S, Liu T, Deng W, Chu X, Jiang C, He W, Xia L, Yang Y, Hong J, Qi Q, Yin W, Liu X, Shi C, Chen M*, Ye W*, Zhang D*. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to anti-angiogenics in colorectal cancer liver metastasis models. The Journal of Clinical Investigation, 2022, 132(19): e157399. (IF: 15.9)

10.Chen MF, Lei XP, Shi CZ, Huang MH, Li XB, Wu BJ, Li ZQ, Han WL, Du B, Hu JY, Nie QL, Mai WQ, Ma N, Xu NH, Zhang XY, Fan CL, Hong AH, Xia MH, Luo LP, Ma AD, Li HH, Yu Q, Chen HR*, Zhang DM*, Ye WC*. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. The Journal of Clinical Investigation, 2017, 127: 3689−3701. (IF: 15.9)

11.Li XB, Qi Q, Li Y, Miao Q, Yin WQ, Pan JH, Zhao Z, Chen XY, Yang F, Zhou XF, Huang MH, Wang CR, Deng LJ, Huang DD, Qi M, Fan SR, Zhang YR, Qiu SH, Deng WQ, Liu TZ, Chen MF*, Ye WC*, Zhang DM*. TCAF2 in pericytes promotes colorectal cancer liver metastasis via inhibiting cold-sensing TRPM8 channel. Advanced Science, 2023, 2302717. (IF: 15.1)

12.Cheng MJ, Zhong LP, Gu CC, Zhu XJ, Chen B, Liu JS, Wang L*, Ye WC*, Li C-C*. Chuang-Chuang Li. Asymmetric total synthesis of bufospirostenin A. Journal of the American Chemical Society, 2020, 142: 12602−12607. (IF: 15.0)

13.Ma N, Hu J, Zhang ZM, Liu WY, Huang MH, Fan YL, Yin XF, Wang J*, Ding K*, Ye WC*, Li ZQ*. 2H-azirine-based reagents for chemoselective bioconjugation at carboxyl residues inside live cells. Journal of the American Chemical Society, 2020, 142: 6051−6059. (IF: 15.0)

14.Ye GN, Huang MH, Li Y, Ouyang J, Chen MF, Wen Q, Li XB, Zeng HH, Long P, Fan ZP, Yin JQ*, Ye WC*, Zhang DM*. The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway. Acta Pharmaceutica Sinica B, 2022, 12(3): 1288–1304. (IF: 14.5) 

15.Qu C, He L, Yao N, Li J, Jiang Y, Li B, Peng S, Hu K, Chen D, Chen G, Huang W, Cao M, Fan J, Yuan Y, Ye WC*, Hong J*. Myofibroblast-specific Msi2 knockout inhibits hepatocellular carcinoma progression in a mouse model. Hepatology, 2021, 74: 458–473. (IF: 13.5) 

16.Guo DJ, Peng YH, Wang LJ, Sun XY, Wang XJ, Liang CM, Yang XM, Li SN, Xu JY, Ye WC*, Jiang B*, Shi L*. Autism-like social deficit generated by Dock4 deficiency is rescued by restoration of Rac1 activity and NMDA receptor function. Molecular Psychiatry, 2021, 26: 1505–1519. (IF: 11.0)

17.Huang MH, Chen MF, Qi M, Ye GN, Pan JH, Shi CZ, Yang YL, Zhao LY, Mo XK, Zhang YR, Li Y, Zhong JC, Lu WJ, Li XB, Zhang JY, Lin JR, Luo LP, Liu TZ, Tang PMK, Hong A, Cao YH*, Ye WC*, Zhang DM*. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. Journal of Extracellular Vesicles, 2021, 10: e12096. (IF: 16.0)

18.Yao N, Wang CR, Liu MQ, Li YJ, Chen WM, Li ZQ, Qi Q, Lu J-J, Fan CL, Chen MF, Qi M, Li XB, Hong J, Zhang DM*, Ye WC*. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. Signal Transduction and Targeted Therapy, 2020, 5: 214. (IF: 39.3)

19.Zhang JY, Liu F, Jin Q, Li XY, Zhan Q, Chen M, Wang SS, Wu ZL*, Ye WC*, Wang L*. Discovery of unusual phloroglucinol–triterpenoid adducts from Leptospermum scoparium and Xanthostemon chrysanthus by building blocks-based molecular networking. Chinese Chemical Letters, 2023: 108881. (IF: 9.1)

20.Cheng MJ, Cao JQ, Yang XY, Zhong LP, Hu LJ, Lu X, Hou BL, Hu YJ, Wang Y, You XF, Wang L*, Ye WC*, Li CC*. Catalytic asymmetric total syntheses of myrtucommuacetalone, myrtucommuacetalone B and callistrilones A, C, D, E. Chemical Science, 2017, 34: 2413−2421. (IF: 8.4)